Is Haldol (Haloperidol) used for agitation in alcohol withdrawal?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 16, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Management of Agitation in Alcohol Withdrawal

Haloperidol (Haldol) is used for agitation in alcohol withdrawal, specifically as an adjunctive therapy for managing severe agitation or psychotic symptoms not controlled by benzodiazepines alone 1.

Key Considerations

  • Dosing: Haloperidol can be administered in doses ranging from 0.5 to 5 mg orally or intramuscularly every 8-12 hours 1.
  • First-Line Treatment: Benzodiazepines, such as lorazepam or diazepam, remain the primary treatment for alcohol withdrawal, with haloperidol used in conjunction for severe cases 1.
  • Duration of Treatment: The duration of haloperidol treatment is typically limited, focusing on controlling acute agitation and preventing harm to the patient or others.
  • Monitoring: Close monitoring is essential, especially in patients with advanced liver disease or those at risk of benzodiazepine abuse, to avoid potential side effects and ensure safe treatment 1.

Adjunctive Therapy

Haloperidol's role as an adjunctive treatment underscores the importance of a comprehensive approach to managing alcohol withdrawal, particularly in cases where agitation or psychotic symptoms are prominent 1.

Evidence Summary

The use of haloperidol in alcohol withdrawal is supported by clinical practice guidelines, which emphasize its adjunctive role in managing severe agitation or psychotic symptoms 1. While benzodiazepines are the cornerstone of treatment, haloperidol provides an additional option for symptom management in specific cases.

From the Research

Haldol (Haloperidol) in Agitation for Alcohol Withdrawal

  • Haldol (Haloperidol) is used as an adjunctive agent in the management of alcohol withdrawal, particularly for symptoms such as agitation and delusions 2.
  • According to a study published in 2019, haloperidol was used by 26.6% of respondents for initial management and 33% for adjunctive management of alcohol withdrawal 2.
  • However, another study published in 1995 states that antipsychotics, including haloperidol, are generally not recommended as first-line therapy for alcohol withdrawal 3.
  • A 2017 review of adjunctive treatment options for severe alcohol withdrawal mentions that antipsychotics may be used in certain cases, but their role is not clearly defined 4.
  • A 2021 article on the treatment of alcohol withdrawal syndrome notes that antipsychotics may be used as alternatives to or in addition to benzodiazepines, especially in cases of protracted delirium with therapeutic resistance 5.

Comparison with Other Agents

  • Benzodiazepines are considered the mainstay of treatment for alcohol withdrawal, with diazepam being a preferred option for moderate to severe cases due to its rapid onset and long elimination half-life 6.
  • Other agents, such as clonidine, barbiturates, and phenobarbital, may also be used as adjunctive treatments for severe alcohol withdrawal 2, 4.
  • The choice of adjunctive agent depends on the specific symptoms and patient characteristics, as well as the potential risks and benefits of each medication 2, 4.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Management of alcohol withdrawal.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 1995

Research

Treatment of Severe Alcohol Withdrawal: A Focus on Adjunctive Agents.

The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians, 2017

Research

[Treatment of alcohol withdrawal syndrome].

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2021

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.